FILED 7/3/03

10/613916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
Sheet 1 of 6	GROUP ART UNIT: unknown 1645	EXAMINER: unknown

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
NMM	*	3,906,092		Hilleman et al.	09-16-1975
	*	5,023,243		Tullis	06-11-1991
	*	5,248,670		Draper et al.	09-28-1993
	*	5,585,479		Hoke et al.	12-17-1996
	*	5,663,153		Hutcherson et al.	09-02-1997
	*	5,723,335		Hutcherson et al.	03-03-1998
	*	5,786,189		Locht et al.	07-28-1998
	*	5,849,719		Carson et al.	12-15-1998
	*	6,194,388	B1	Krieg et al.	02-27-2001
	*	6,207,646	B1	Krieg et al.	03-27-2001
	*	6,214,806	B1	Krieg et al.	04-10-2001
	*	6,218,371	B1	Krieg et al.	04-17-2001
	*	6,239,116	B1	Krieg et al.	05-29-2001
	*	6,339,068	B1	Davis et al.	01-15-2002
		6,552,006	B2	Raz et al.	04-22-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
NMM	*	EP	0468520	A3		01-29-1992	
	*	EP	0302758	B1		11-08-1989	
	*	WO	91/12811			09-05-1991	
	*	WO	92/03456			04-05-1992	
	*	WO	92/18522			10-29-1992	
	*	WO	92/21353			12-10-1992	
	*	WO	94/19945			09-15-1994	
	*	WO	95/05853			03-02-1995	
	*	WO	95/26204			10-05-1995	
	*	WO	96/02555	A1		02-01-1996	
	*	WO	96/35782			11-14-1996	
	*	WO	97/28259			08-07-1997	
	*	WO	98/14210			04-09-1998	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
NMM	*	ADYA N et al., Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. *Proc Natl Acad Sci* USA 91(12):5642-6, Jun. 7, 1994.		
	*	ANGIER N, Microbe DNA seen as alien by immune system, *New York Times*, Apr. 11, 1995.		
NMM	*	AZAD RF et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region, *Antimicrobial Agents and Chemotherapy*, 37:1945-1954, Sep. 1993.		

10/613916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
Sheet 2 of 6	GROUP ART UNIT: unknown 1645	EXAMINER: unknown

NMM		*	AZUMA, Biochemical and immunological studies on cellular components of tubercle bacilli, *Kekkaku*, 69(9):45-55 (1992).		
		*	BALLAS ZK et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J Immunol* 157(5):1840-5 (1996).		
		*	BAYEVER E, systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial, *Antisense Res Dev*, 3:383-390 (1993).		
		*	BENNETT RM et al., DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA. *J Clin Invest* 76(6):2182-90 (1985).		
		*	BIOLABS 1988-1989 Catalog, Random Primer #s 1230, 1601, 1602.		
		*	BLAXTER et al., Genes expressed in Brugia malayi infective third stage larvae, *Mol Biochem Parasitol*, 77:77-93 (Apr. 1996).		
		*	BOGGS RT et al., Characterization and modulation of immune stimulation by modified oligonucleotides. *Antisense Nucleic Acid Drug Dev* 7(5):461-71, Oct. 1997.		
		*	BRANDA et al., Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1, *Biochem Pharmacol*, 45(10):2037-2043 (1993).		
		*	BRANDA RF et al., Amplification of antibody production by phosphorothioate oligodeoxynucleotides. *J Lab Clin Med* 128(3):329-38, Sep. 1996.		
		*	BRISKIN M et al., Lipopolysaccharide-unresponsive mutant pre-B-cell lines blocked in NF-kappa B activation, *Mol Cell Biol*, 10:1:422-5 (1990).		
		*	CHACE J et al., Regulation of differentiation in CD5+ and conventional B cells, *Clin Immunol Immunopathol*, 68(3):327-332 (1993).		
		*	CHANG YN et al., The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements. *J Virol* 64(1):264-77, Jan. 1990.		
		*	CHU RS et al., CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. *J Exp Med* 186(10):1623-31, Nov. 17, 1997.		
		*	COWDERY J et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides, *J Immunol*, 156:12:4570-5 (1996).		
		*	CROSBY SD et al., The early responses gene NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG (GSG) element-binding protein family, *Mol Cell Biol*, 2:3835-3841 (1991).		
		*	CRYSTAL R, Transfer of genes to humans: early lessons and obstacles to success, *Science*, 270:404-410 (1995).		
		*	ENGLISCH et al., Chemically modified oligonucleotides as probes and inhibitors, *Angew Chem Int Ed Engl*, 30:613-629 (1991).		
		*	ERB KJ et al., Infection of mice with Mycobacterium bovis-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. *J Exp Med* 187(4):561-9, Feb. 16, 1998.		
		*	ETLINJER, Carrier sequence selection--one key to successful vaccines, *Immunology Today*, 13(2):52-55 (1992).		
		*	European Patent Office, International Search Authority--Search Report, PCTUS95/01570, Jul. 11, 1995.		
		*	FOX RI, Mechanism of action of hydroxychloroquine as anantirheumatic drug, Chem Abstracts 120:15, Abstract No. 182630 (Apr. 29, 1994).		
		*	GURA T, Antisense has growing pains, *Science*, 270:575-576 (1995).		
		*	HADDEN J et al., Immunopharmacology, *JAMA*, 268:20:2964-2969 (1992).		
		*	HADDEN J et al., Immunostimulants, *TIPS*, 141:169-174 (1993).		
		*	HALPERN MD et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. *Cell Immunol* 167(1):72-8 (1996).		

10/613,916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
	GROUP ART UNIT: unknown 1645	EXAMINER: unknown
Sheet 3 of 6		

NMM	*	HATZFELD J, Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides, *J Exp Med*, 174:925-929 (1991).		
	*	HIGHFIELD PE, Sepsis: the more, the murkier, *Biotechnology*, 12:828, Aug. 12, 1994.		
	*	HOEFFLER JP et al., Identification of multiple nuclear factors that interact with cyclic adenosine 3',5'-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions. *Mol Endocrinol* 5(2):256-66, Feb. 1991.		
	*	IGUCHI-ARIGA SM et al., CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. *Genes Dev* 3(5):612-9, May 1989.		
	*	ISHIKAWA R et al., IFN induction and associated changes in splenic leukocyte distribution. *J Immunol* 150(9):3713-27, May 1, 1993.		
	*	IVERSEN P et al., Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion, *Antisense Res Dev*, 4:43-52 (1994).		
	*	JAKWAY J et al., Growth regulation of the B lymphoma cell line WEHI-231 by anti-immunoglobulin, lipopolysaccharide, and other bacterial products, *J Immunol*, 137:7:2225-31 (1996).		
	*	JAROSZEWSKI J et al., Cellular uptake of antisense oligonucleotides, *Adv Drug Delivery Rev*, 6:3:235-50 (1991).		
	*	KATAOKA T et al., Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of Mycobacterium bovis BCG, *Jpn J Cancer Re.*, 83:244-247, Mar. 1992.		
	*	KIMURA Y et al., Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN, *J Biochem*, 116(5):991-994 (1994).		
	*	KLINE JN et al., CpG motif oligonucleotides are effective in prevention of eosinophilic inflammation in a murine model of asthma. *J Invest Med* 44(7):380A (1996).		
	*	KLINE JN et al., CpG oligonucleotides can reverse as well as prevent TH2-mediated inflammation in a murine model of asthma. *J Invest Med* 45(7):298A (1997).		
	*	KLINE JN et al., Immune redirection by CpG oligonucleotides. Conversion of a Th2 response to a Th1 response in a murine model of asthma. *J Invest Med* 45(3):282A (1997).		
	*	KLINMAN DM et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. *Proc Natl Acad Sci* USA 93(7):2879-83 (1996).		
	*	KRIEG AM et al, Phosphorothioate oligodeoxynucleotides: antisense or anti-protein?, *Antisense Res Dev*, 5:241 (1995).		
	*	KRIEG AM et al, The role of CpG dinucleotides in DNA vaccines, *Trends in Microbiology*, 6:23-27, Jan. 1998.		
	*	KRIEG AM et al., A role for endogenous retroviral sequences in the regulation of lymphocyte activation, *J Immunol* 143(8):2448-51, Oct. 15, 1989.		
	*	KRIEG AM et al., CpG DNA: A pathogenic factor in systemic lupus erythematosus? *J Clin Immunol*, 15(6):284-292 (1995).		
	*	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature* 374:546-9, 6 Apr. 1995.		
	*	KRIEG AM et al., Leukocyte stimulation by oligodeoxynucleotides, *Applied Antisense Oligonucleotide Technology* 431-448 (1998),.		
	*	KRIEG AM et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy, *Proc Natl Acad Sci USA*, 90:1048-1052 (1993).		
↓	*	KRIEG AM et al., Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. *Antisense Nucleic Acid Drug Dev* 6(2):133-9, Summer 1996.		

10/613916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
Sheet 4 of 6	GROUP ART UNIT: unknown 1645	EXAMINER: unknown

NMM	*	KRIEG AM et al., Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. *Antisense Res Dev* 1(2):161-71, Summer 1991.		
	*	KURAMOTO et al., Oligonucleotide sequences required for natural killer cell activation, *Jpn J Cancer Res*, 83:1128-1131, Nov. 1992.		
	*	LEONARD GA et al., Conformation of guanine 8-oxoadenine base pairs in the crystal structure of d(CGCGAATT(O8A)GCG), *Biochemistry*, 31(36):8415-8420 (1992).		
	*	LIPFORD G et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants, *Eur J Immunol*, 27(9):2340-4 (1997).		
	*	LIPFORD G et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines, *Eur J Immunol*, 12(27):3420-3426 (1997).		
	*	MACFARLANE DE et al., Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. *J Immunol* 160(3):1122-31, Feb. 1, 1998.		
	*	MASTRANGELO MJ et al., Gene therapy for human cancer: an essay for clinicians. *Seminars Oncology*, 23(1):4-21 (1996).		
	*	MATSON S et al., Nonspecific suppression of [^{3}H]thymidine incorporation by control oligonucleotides. *Antisense Res Dev* 2(4):325-30, Winter 1992.		
	*	MCINTYRE K et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation, *Antisense Res Dev*, 3(4):309-322 (1993).		
	*	MESSINA et al., Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA, *J Immunol*, 147(6):1759-1764, Sep. 15, 1991.		
	*	MESSINA, et al., The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens, *Cell Immunol*, 147:148-157 (1993).		
	*	MOJCIK C et al., Administration of a phosphorothioate oligonucleotide antisense murine endogenous retroviral MCF env causes immune effect in vivo in a sequence-specific manner, *Clin Immunol Immunopathol*, 67(2):130-136 (1993).		
	*	MOTTRAM et al., A novel CDC2-related protein kinase from leishmania mexicana, LmmCRK1, is post-translationally regulated during the life cycle, *J Biol Chem*, 268:28 21044-21052 (Oct. 1993).		
	*	NYCE J et al., DNA antisense therapy for asthma in an animal model, *Nature*, 385:721-5 (1997).		
	*	PISETSKY D, Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides, *Molecular Biology Reports*, 18:217-221 (1993).		
	*	PISETSKY DS et al., Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. *Life Science*, 54:101-107 (1994).		
	*	PISETSKY DS, Immunological consequences of nucleic acid therapy, *Antisense Res Dev*, 5:219-225 (1995).		
	*	PISETSKY DS, The immunological properties of DNA, *J Immunol*, 156:421-423 (1996).		
	*	QUDDUS J et al., Treating activated CD4+ T cells with either of two distinct DNA methyltransferase ihibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. *J Clin Invest* 92(1):38-53, Jul. 1993.		
	*	RAZ E et al., Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses, *Proc Natl Acad Sci USA*, 91:9519-9523 (1994).		
	*	ROJANASAKUL Y, Antisense oligonucleotide therapeutics: drug delivery and targeting, *Advanced Drug Delivery Reviews*, 18:115-131 (1996).		
	*	ROMAN M et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. *Nat Med* 3(8):849-854, Aug. 1997.		
↓	*	SATO et al., Immunostimulatory DNA sequences necessary for effective intradermal gene immunization, *Science*, 273:352-354 (1996).		

10/613916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
Sheet 5 of 6	GROUP ART UNIT: unknown 1645	EXAMINER: unknown

NMM	*	SCHNELL N et al., Identification and characterization of a Saccharomyces cerevisiae gene (PAR1) conferring resistance to iron chelators, *Eur J Biochem*, 200:487-493 (1991).		
	*	SCHWARTZ DA et al., CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. *J Clin Invest* 100(1):68-73, Jul. 1, 1997.		
	*	SHIRAKAWA T et al., The inverse association between tuberculin responses and atopic disorder. *Science* 275(5296):77-9, Jan. 3, 1997.		
	*	SPARWASSER T et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. *Eur J Immunol* 27(7):1671-9, Jul. 1997.		
	*	STEIN CA et al., Oligodeoxynucleotides as inhibitors of gene expression: a review, *Cancer Res*, 48:2659-2668 (1988).		
	*	STULL RA et al., Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects, *Pharm Res.*, 12(4):465-483 (1995).		
	*	SUBRAMANIAN et al., Theoretical considerations on the `spine of hydration` in the minor groove of d(CGCGAATTCGCG) d(CGGCTTAAGCGC): Monte Carlo computer simulation, *Proc Natl Acad Sci* USA, 85:1836-1840, Mar. 1988.		
	*	TANAKA T et al., An antisense oligonucleotide complementary to a sequence in I gamma 2b increases gamma 2b germline transcripts stimulates B cell DNA synthesis and inhibits immunoglobulin secretion, *J Exp Med*, 175: 597-607 (1992).		
	*	The New England Biolabs Catalog, 1988-1989, item #1230.		
	*	TOKUNAGA T et al., A synthetic single-stranded DNA, poly (dG, dC), induces interferon-α/β and -γ, augments natural killer activity and suppresses tumor growth, *Jpn J Cancer Res*, 79:682-686, Jun. 1988.		
	*	TOKUNAGA T et al., synthetic oligonucleotides with particular base sequences from the cDNA encoding proteins of Mycobacterium bovis BCG induce interferons and activate natural killer cells, *Microbiol Immunol*, 36(1):55-66 (1992).		
	*	UHLMANN, et al., Antisense oligonucleotides: a new therapeutic principle, *Chem Rev*, 90:543-584 (1990).		
	*	WAGNER RW, Gene inhibition using antisense oligodeoxynucleotides, *Nature*, 372:333-335 (1994).		
	*	WALLACE et al., Oligonucleotide probes for the screening of recombinant DNA libraries, *Methods Enzymol*, 152:432-442 (1987).		
	*	WEISS R, Upping the antisense ante: scientists bet on profits from reverse genetics, *Science*, 139:108-109 (1991).		
	*	WHALEN RG, DNA vaccines for emerging infection diseases: what if?, *Emerg Infect Dis*, 2(3):168-175 (1996).		
	*	WU GY et al., Receptor-mediated gene delivery and expression in vivo, *J Biol Chem*, 263:14621-14624 (1988).		
	*	WU-PONG S, Oligonucleotides: opportunities for drug therapy and research, *Pharmaceutical Technology*, 18:102-114 (1994).		
	*	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells, and inhibits tumor growth, *Microbiol Immunol*, 36(9):983-997 (1992).		
	*	YAMAMOTO S et al., In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. *Jpn J Cancer Res* 79:866-73, Jul. 1988.		
	*	YAMAMOTO S et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce inf and augment INF-mediated natural killer activity, *J Immunol*, 148(12):4072-4076, Jun. 15, 1992.		
	*	YAMAMOTO S, Mode of action of oligonucleotide fraction extracted from Mycobacterium bovis BCG, *Kekkaku*, 69(9):29-32 (1994).		

10/613916

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: unassigned	ATTY. DOCKET NO.: C01039.70075.US
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: Herewith	
	APPLICANT: Krieg et al.	
Sheet 6 of 6	GROUP ART UNIT: unknown 1645	EXAMINER: unknown

NMM	*	YAMAMOTO T et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length, *Antisense Res Dev*, 4:119-123 (1994).		
	*	YAMAMOTO T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence AACGTT to murine splenocytes enhances interferon production and natural killer activity, *Microbiol Immunol*, 38(10):831-836 (1994).		
	*	YAMAMOTO T et al., Synthetic oligonucleotides with certain palindromes stimulate interferon production of human peripheral blood lymphocytes in vitro, *Jpn J Cancer Res*, 85:775-779 (1994).		
	*	YI AK et al., IFN-γ promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligonucleotides, *J Immunol*, 156:558-564 (1996).		
	*	YI AK et al., Rapid immune activation by CpG motifs in bacterial DNA, *J Immunol*, 157:5394-5402 (1996).		
	*	ZHAO Q et al., Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. *Antisense Res Dev* 3(1):53-66, Spring 1993.		
	*	ZHAO Q et al., Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. *Blood* 84(11):3660-6, Dec. 1, 1994.		

EXAMINER	DATE CONSIDERED
/N. M. Minnifield/ (08/07/2006)	08/07/2006

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/818,918, filed on March 27, 2001, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

12/15/03

B. The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications (copies enclosed) that may contain subject matter related to this application:

NMM

Docket No.	Serial No.	Filing Date	Inventor
C1037.70016US00	09/009,634	01-20-1998	Hutcherson et al.
C1039.70020US00	09/337,584	06-21-1999	Krieg et al.
C1039.70023US00	09/337,636	06-21-1999	Krieg
C1039.70022US00	09/337,893	06-21-1999	Krieg
C1039.70043US00	09/629,477	07-31-2000	Krieg et al.
C1039.70042US00	09/630,319	07-31-2000	Krieg et al.
C1039.70041US00	09/655,319	09-05-2000	Krieg et al.
C1041.70010US00	09/786,436	03-02-2001	Wagner et al.
C1039.70057US00	09/965,101	09-26-2001	Davis et al.
C1039.70062US00	10/187,489	07-02-2002	Krieg et al.
C1039.70069US00	10/314,578	12-09-2002	Krieg et al.
C1041.70035US00	10/373,381	02-25-2003	Wagner et al.
C1039.70070US00	10/382,822	03-06-2003	Krieg et al.
C1041.70037US00	10/407,952	04-04-2003	Lipford et al.
C1039.70072US00	10/434,696	05-09-2003	Davis et al.
C1039.70071US00	10/435,656	05-09-2003	Krieg et al.
C1039.70077US00	10/619,279	07-14-2003	Krieg
C1039.70078US00	10/627,331	07-25-2003	Krieg et al.
C1039.70079US00	10/627,413	07-25-2003	Krieg et al.

/N. M. Minnifield/ (08/07/2006)

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

1/28/04

The Applicant would like to bring to the Examiner's attention the following co-pending applications (copies enclosed) that may contain subject matter related to this application:

NMM

Docket No.	Serial No.	Filing Date	Inventor
C1037.70046US00	10/445,247	06-05-2003	Krieg incorrect?
C1037.70045US00	10/613,228	07-03-2003	Krieg
C1037.70042US00	10/613,524	07-03-2003	Krieg
C1037.70044US00	10/613,736	07-03-2003	Krieg
C1037.70043US00	10/613,739	07-03-2003	Krieg
C1037.70041US00	10/613,749	07-03-2003	Krieg
C1039.70082US00	10/631,676	07-30-2003	Krieg et al.
C1037.70049US00	10/643,141	08-18-2003	Hutcherson et al.
C1037.70048US00	10/644,052	08-19-2003	Jurk et al.
C1039.70084US00	10/649,584	08-25-2003	Krieg et al.
C1037.70051US00	10/666,733	09-19-2003	Bratzler et al.
C1041.70040US00	10/666,844	09-19-2003	Lipford et al.
C1037.70052US00	10/668,050	09-22-2003	Bratzler et al.
C1039.70083US00	10/690,495	10-21-2003	Krieg et al.
C1039.70021US01	10/719,493	11-21-2003	Krieg et al.
C1037.70038US01	10/735,592	12-11-2003	Krieg et al.
C1039.70073US00	10/743,625	12-22-2003	Krieg et al

/N. M. Minnifield/ (08/07/2006)

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).